<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23238" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hypertrophic Obstructive Cardiomyopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Raj</surname>
            <given-names>Marc A.</given-names>
          </name>
          <aff>Bodor Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ranka</surname>
            <given-names>Sagar</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Amandeep</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marc Raj declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sagar Ranka declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amandeep Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23238.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hypertrophic obstructive cardiomyopathy (HOCM), historically referred to as idiopathic hypertrophic subaortic stenosis, is a relatively common disorder. HOCM is a significant cause of sudden cardiac death in young people, including well-trained athletes, and affects men and women equally across all races. In most patients, it results from asymmetric septal hypertrophy, causing outflow obstruction of the left ventricle. Diagnosing and challenging medical health professionals in evaluating at-risk athletes is difficult. This activity reviews the evaluation and management of hypertrophic obstructive cardiomyopathy. It highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess&#x000a0;the recommended management of hypertrophic obstructive cardiomyopathy.</p></list-item><list-item><p>Evaluate&#x000a0;the typical presentation for a patient with hypertrophic obstructive cardiomyopathy.</p></list-item><list-item><p>Interpret&#x000a0;the pathophysiology of hypertrophic obstructive cardiomyopathy.</p></list-item><list-item><p>Communicate&#x000a0;the interprofessional team strategies for improving care coordination and communication regarding the management of patients with hypertrophic obstructive cardiomyopathy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23238&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23238">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23238.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hypertrophic obstructive cardiomyopathy (HOCM) is a relatively common disorder. Historically, it has been referred to as idiopathic hypertrophic subaortic stenosis. HOCM is a significant cause of sudden cardiac death in young people, including well-trained athletes, affecting men and women equally across all races. In most patients, it results from asymmetric septal hypertrophy, causing outflow obstruction of the left ventricle. Diagnosing and challenging medical health professionals in evaluating at-risk athletes is difficult. Unfortunately, HOCM is often not diagnosed until a significant cardiac event has occurred.<xref ref-type="bibr" rid="article-23238.r1">[1]</xref><xref ref-type="bibr" rid="article-23238.r2">[2]</xref><xref ref-type="bibr" rid="article-23238.r3">[3]</xref><xref ref-type="bibr" rid="article-23238.r4">[4]</xref>&#x000a0;The hypertrophy can occur in any segment of the left ventricle but is most common in the interventricular septum. This often results in obstruction of blood flow through the left ventricular outflow tract. HOCM is a genetic disorder. Defects in several genes have been identified that result in septal hypertrophy. The condition is usually asymptomatic in children but may first present with sudden death in teenagers and adolescents.</p>
      </sec>
      <sec id="article-23238.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The familial form of HOCM is an autosomal dominant genetically transmitted disorder. It is the most common genetically transmitted cardiomyopathy. It can also occur in individuals without a family history secondary to de novo mutations. HOCM results from a gene mutation that encodes for&#x000a0;1 of the&#x000a0;9&#x000a0;sarcomere proteins, such as B-myosin heavy chain, troponin, actin, and titin. The mutations cause structural abnormalities in myofibril and myocytes that have the potential to lead to abnormal force generation and conduction abnormalities. The consequences of this are a phenotype for asymmetric left ventricular hypertrophy in the absence of other causes.&#x000a0;<xref ref-type="bibr" rid="article-23238.r5">[5]</xref><xref ref-type="bibr" rid="article-23238.r6">[6]</xref><xref ref-type="bibr" rid="article-23238.r7">[7]</xref>&#x000a0;Other causes of HOCM include:</p>
        <list list-type="order">
          <list-item>
            <p>Heightened sympathetic stimulation due to excess catecholamine secretion or decreased uptake</p>
          </list-item>
          <list-item>
            <p>Abnormally thickened coronary arteries, which may not dilate normally. This may lead to ongoing myocardial ischemia that eventually leads to ventricular fibrosis and compensatory hypertrophy</p>
          </list-item>
          <list-item>
            <p>Abnormal microcirculation that prevents the normal contractile function of the myofibrils</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23238.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>HOCM occurs in men and women with equal distribution across all races. Females tend to be more symptomatic, causing more disability, and present at a younger age. A 1995 study by Maron et al concluded that it occurs at a rate of 1:500 in the general adult population. In the United States alone, there are fewer than 100 deaths per year due to HOCM at a rate of 1:220,000 athletes. Most patients present in the second/third decade of life. However, some adults may present between the fourth and sixth decades of life.</p>
      </sec>
      <sec id="article-23238.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>HOCM can be classified as obstructive or non-obstructive. There is some degree of asymmetric left ventricular hypertrophy. The degree of obstruction and clinical presentation depends on the extent of hypertrophy. It most commonly affects the ventricular septum (about 2/3 of patients), although any portion of the left ventricle can be affected.&#x000a0;Dynamic outflow obstruction in HOCM is due to the systolic anterior motion of the anterior leaflet of the mitral valve. This is due to impingement of the mitral valve leaflets on the hypertrophied basal septum. The outflow tract obstruction is dynamic and caused by a pressure gradient, which pulls the anterior leaflet of the mitral valve anteriorly, further leading to outflow tract obstruction. The degree of obstruction is dependent upon contractility and loading conditions. In 25% of patients, the obstruction can exist at rest, but in about 70% of patients, it can be brought about with provocative maneuvers.&#x000a0;Most patients with HOCM have an abnormal diastolic function. This increases left ventricular pressures, impairing ventricular filling, which further exacerbates obstruction. Because the coronary vessels are filled during diastole, in combination with outflow tract obstruction and ventricular stiffness, there is an increased risk for myocardial ischemia. This may be responsible for ventricular arrhythmias and sudden death. In severe cases, this can occur at rest. More commonly, it occurs with provocative maneuvers such as exercise during increased myocardial demand.</p>
      </sec>
      <sec id="article-23238.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histology may reveal the disorganization of the muscle fibers, cell-to-cell disarray, and gross disorganization of the architecture. Fibrosis may be evident. The coronary arteries may be intramural and have a reduced diameter.</p>
      </sec>
      <sec id="article-23238.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough history and physical should be performed. All patients should be asked about a family history of HOCM and sudden cardiac death. A majority of patients are asymptomatic. Dyspnea is the most common complaint among symptomatic patients. Patients may also complain of presyncope, syncope, angina, palpitations (secondary to arrhythmia), or dizziness. Symptoms are frequently exacerbated by exertion. Severe cases will present, like congestive heart failure with paroxysmal nocturnal dyspnea, leg edema, and orthopnea. The most devastating presentation is sudden cardiac death. The physical exam&#x000a0;does not provide a definitive diagnosis but should provide clues to increase clinical suspicion. Patients may present with a jugular venous pulse with prominent A wave, S4 heart sound, split-second heart sound (may paradoxically split in severe outflow tract obstruction), double carotid pulse, systolic ejection crescendo-decrescendo murmur, laterally displaced apical precordial impulse that may be abnormal forceful or enlarged, or a holosystolic murmur at the apex and axilla of mitral regurgitation with systolic anterior wall motion. The lung exam should be normal. The murmur and the gradient across the left&#x000a0;ventricular outflow tract will decrease with an increase in preload (squatting) or afterload (handgrip). In addition, the gradient and the murmur will increase with a decrease in preload (Valsalva maneuver, diuretics, standing).</p>
        <list list-type="bullet">
          <list-item>
            <p>Certain maneuvers can affect murmurs auscultated in HOCM.</p>
          </list-item>
          <list-item>
            <p>Handgrip will increase ventricular volume, decreasing&#x000a0;left ventricle outflow gradient and decreasing murmur intensity.</p>
          </list-item>
          <list-item>
            <p>Valsalva maneuver will decrease ventricular volume, increase the&#x000a0;left ventricle outflow gradient, and increase&#x000a0;murmur intensity.</p>
          </list-item>
          <list-item>
            <p>Beta-blockers will increase ventricular volume, decrease&#x000a0;left ventricle outflow gradient, and decrease murmur intensity.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23238.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Lab studies should be normal, but brain natriuretic peptide may be elevated with severe disease. Genetic testing is available and diagnostic but is reserved for patients with significant family histories or those who exhibit clear symptoms. The American Heart Association is currently opposed to routine screening for genetic markers. A chest x-ray may be normal, but left ventricular hypertrophy may be seen. An electrocardiogram may show left ventricular hypertrophy. It may also show arrhythmias such as atrial fibrillation or non-sustained ventricular tachycardia. However, electrocardiograms can frequently be normal. 2D echocardiography is the primary imaging modality used to diagnose HOCM. The echo has an 80% diagnostic accuracy for HOCM. Direct visualization and relatively accurate measurements of the septum and left ventricular wall sizes can be done. It will be able to show increased flow velocity along the left ventricular outflow tract. Color flow Doppler can show mitral valve regurgitation. Reduced&#x000a0;left ventricle compliance can be seen in diastolic dysfunction. The key features of HOCM include the asymmetric septal wall thickness (more than 15 mm) and systolic anterior motion of the anterior mitral valve leaflet. The posterior septal wall is usually much thicker than the anterior septal wall. The narrowing of the left&#x000a0;ventricular outflow tract is often obvious. Cardiac MRI is considered the gold standard for diagnosing&#x000a0;left ventricle wall properties and should be performed in patients suspected of having HOCM with a normal or inconclusive echocardiogram. Cardiac catheterization is not required for diagnosis but may be performed to accurately determine the degree of outflow tract obstruction, left ventricle anatomy, mitral valve regurgitation, and coronary artery patency. Radionuclide imaging may reveal reversible defects in the absence of coronary artery disease.</p>
      </sec>
      <sec id="article-23238.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment is based on the severity of symptoms. Mild disease is treated with lifestyle modifications. Patients should be strongly advised to avoid strenuous exercise and heavy lifting. The first line of medical treatment for symptomatic HOCM is beta blockers, though cardiac selective calcium channel blockers may be used. Angiotensin-converting enzyme inhibitors and nitrates should be avoided as these medications decrease afterload, worsening&#x000a0;left ventricle&#x000a0;outflow tract obstruction.&#x000a0;<xref ref-type="bibr" rid="article-23238.r8">[8]</xref><xref ref-type="bibr" rid="article-23238.r9">[9]</xref><xref ref-type="bibr" rid="article-23238.r10">[10]</xref><xref ref-type="bibr" rid="article-23238.r11">[11]</xref>&#x000a0;Surgical intervention is reserved for patients resistant to lifestyle and medical management or those with an outflow gradient of 50mmhg or more. Septal myectomy is the surgical treatment of choice in young healthy patients. Alcohol septal ablation is a newer percutaneous technique usually limited to older patients for whom an open procedure would be considered risky.</p>
      </sec>
      <sec id="article-23238.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for hypertrophic obstructive cardiomyopathy include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Aortic valve stenosis</p>
          </list-item>
          <list-item>
            <p>Restrictive cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Pericardial tamponade</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23238.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Mortality rates for HOCM have improved but still range from 1-6%. Sudden death is the most common cause of death in young people. Studies show that midventricular obstruction is associated with a high risk of apical aneurysm formation, cardiac symptoms, and sudden death compared to patients who did not have the midventricular obstruction. Death is often sudden and typically associated with a sporting activity. Screening of first-degree relatives is now done to identify individuals at high risk for death. Patients with HOCM may develop a variety of atrial and ventricular arrhythmias. Heart failure is likely in patients with severe diastolic dysfunction. The condition is progressive, and eventually, all patients will develop symptoms.</p>
      </sec>
      <sec id="article-23238.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The complications that can manifest with hypertrophic obstructive cardiomyopathy are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ventricular arrhythmias</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Infective endocarditis of the mitral valve</p>
          </list-item>
          <list-item>
            <p>Atrial fibrillation</p>
          </list-item>
          <list-item>
            <p>Embolic phenomenon</p>
          </list-item>
          <list-item>
            <p>Sudden death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23238.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of HOCM is done by an interprofessional team that consists of a cardiologist, electrophysiologist, cardiac surgeon, and internist. The primary care provider and nurse practitioner usually play a role in follow-up after treatment. The treatment of HOCM is based on&#x000a0;the severity of symptoms. Mild disease is treated with lifestyle modifications. Patients should be strongly advised to avoid strenuous exercise and heavy lifting. First-line medical treatment for symptomatic HOCM is beta blockers, though cardiac selective calcium channel blockers may be used. Angiotensin-converting enzyme&#x000a0;inhibitors and nitrates should be avoided as these medications decrease afterload, worsening&#x000a0;left ventricle outflow tract obstruction. The pharmacist must educate the patient on the importance of medication compliance. Surgical intervention is reserved for patients resistant to lifestyle and medical management or those with an outflow gradient of 50mmhg or more. Septal myectomy is the surgical treatment of choice in young healthy patients. Alcohol septal ablation is a newer percutaneous technique usually limited to older patients for whom an open procedure would be considered risky. The outlook for patients who are treated is good, but those who fail to comply with medical or surgical therapy have a very high risk of sudden death. Because the disorder also runs in families, siblings, and other family members should be screened for the disorder.<xref ref-type="bibr" rid="article-23238.r6">[6]</xref><xref ref-type="bibr" rid="article-23238.r12">[12]</xref><xref ref-type="bibr" rid="article-23238.r13">[13]</xref></p>
      </sec>
      <sec id="article-23238.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23238&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23238">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/hypertrophic-obstructive-cardiomyopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23238">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23238/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23238">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23238.s15">
        <title>References</title>
        <ref id="article-23238.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czimbalmos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Csecs</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Suhai</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>Sydo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dohy</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Apor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vago</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The demanding grey zone: Sport indices by cardiac magnetic resonance imaging differentiate hypertrophic cardiomyopathy from athlete's heart.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>e0211624</fpage>
            <pub-id pub-id-type="pmid">30763323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aljeaid</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Wakefield</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chadwell</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Prada</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of pathogenic and likely pathogenic variants in the RASopathy genes in patients who have had panel testing for cardiomyopathy.</article-title>
            <source>Am J Med Genet A</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>179</volume>
            <issue>4</issue>
            <fpage>608</fpage>
            <page-range>608-614</page-range>
            <pub-id pub-id-type="pmid">30762279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Preoperative NT-proBNP Predicts Midterm Outcome After Septal Myectomy.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2019</year>
            <month>Feb</month>
            <day>19</day>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>e011075</fpage>
            <pub-id pub-id-type="pmid">30760079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borer</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Atar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marciniak</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Serebruany</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights.</article-title>
            <source>Thromb Haemost</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>119</volume>
            <issue>3</issue>
            <fpage>355</fpage>
            <page-range>355-357</page-range>
            <pub-id pub-id-type="pmid">30759487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fern&#x000e1;ndez-Ruiz</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Modulating myosin function to treat hypertrophic cardiomyopathy.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>201</fpage>
            <pub-id pub-id-type="pmid">30755739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Driel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nijenkamp</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huurman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Michels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Velden</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sex differences in hypertrophic cardiomyopathy: new insights.</article-title>
            <source>Curr Opin Cardiol</source>
            <year>2019</year>
            <month>May</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>254</fpage>
            <page-range>254-259</page-range>
            <pub-id pub-id-type="pmid">30747730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marrocco</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bogomolovas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ehler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dos Remedios</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>PKC and PKN in heart disease.</article-title>
            <source>J Mol Cell Cardiol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>128</volume>
            <fpage>212</fpage>
            <page-range>212-226</page-range>
            <pub-id pub-id-type="pmid">30742812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mazzarotto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Whiffin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Buchan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Midwinter</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wilk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Felkin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ingold</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Govind</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mazaika</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Allouba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>de Marvao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ashley</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Colan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Michels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Jacoby</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>PJR</given-names>
              </name>
              <name>
                <surname>Olivotto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy.</article-title>
            <source>Genome Med</source>
            <year>2019</year>
            <month>Jan</month>
            <day>29</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <pub-id pub-id-type="pmid">30696458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raffa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Falletta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morsolini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turrisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nugara</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Scarlata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clemenza</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pilato</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Surgical management of hypertrophic obstructive cardiomyopathy: the role of mitral valve].</article-title>
            <source>G Ital Cardiol (Rome)</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>109</fpage>
            <page-range>109-116</page-range>
            <pub-id pub-id-type="pmid">30747926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modaff</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Hegde</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wyman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rahko</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Usefulness of Focused Screening Echocardiography for Collegiate Athletes.</article-title>
            <source>Am J Cardiol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>169</fpage>
            <page-range>169-174</page-range>
            <pub-id pub-id-type="pmid">30348435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Emet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dadashov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sonsoz</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Cakir</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elitok</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bilge</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mercanoglu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oncul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adalet</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Onur</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Galectin-3: A Novel Biomarker Predicts Sudden Cardiac Death in Hypertrophic Cardiomyopathy.</article-title>
            <source>Am J Med Sci</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>356</volume>
            <issue>6</issue>
            <fpage>537</fpage>
            <page-range>537-543</page-range>
            <pub-id pub-id-type="pmid">30342718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinojar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-M&#x000e9;ndez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esteban</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Plaza-Martin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-G&#x000f3;mez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carbonell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rinc&#x000f3;n</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>N&#x000e1;cher</surname>
                <given-names>JJJ</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Golf&#x000ed;n</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of left atrial function by cardiovascular magnetic resonance feature tracking in hypertrophic cardiomyopathy.</article-title>
            <source>Int J Cardiovasc Imaging</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>1055</fpage>
            <page-range>1055-1065</page-range>
            <pub-id pub-id-type="pmid">30706353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23238.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bogachev-Prokophiev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Afanasyev</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Zheleznev</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pivkin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharifulin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kozmin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karaskov</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Septal Myectomy With Vs Without Subvalvular Apparatus Intervention in Patients With Hypertrophic Obstructive Cardiomyopathy: A Prospective Randomized Study.</article-title>
            <source>Semin Thorac Cardiovasc Surg</source>
            <year>2019</year>
            <season>Autumn</season>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>424</fpage>
            <page-range>424-431</page-range>
            <pub-id pub-id-type="pmid">30641129</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
